A Search for Predictive Factors for Hypersensitivity Reactions to Paclitaxel and Platinum Salts in Chemotherapy for Gynecologic Pelvic Neoplasms

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Gynecologic and Obstetric Investigation

• Publication date

  2012-05-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000336772PMID 22652565
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Association between Obesity and Atopy in Adults

  2010cited by this paper
• Female sex hormones mediate the allergic lung reaction by regulating the release of inflammatory mediators and the expression of lung E-selectin in rats

  2010cited by this paper
• Association of CYP1B1 with hypersensitivity induced by Taxane therapy in breast cancer patients

  2010cited by this paper
• Obesity and obesity related co‐morbidities in a referral population of children with asthma

  2009cited by this paper
• Hypersensitivity reactions to antineoplastic agents: an overview

  2009influential reference
• Pharmacogenomics of Taxane/Platinum Therapy in Ovarian Cancer

  2009cited by this paper
• Body mass index in Belgian schoolchildren and its relationship with sensitization and allergic symptoms

  2009cited by this paper
• Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer.

  2007cited by this paper
• Diagnostic and predictive value of skin testing in platinum salt hypersensitivity.

  2007cited by this paper
• Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients.

  2006cited by this paper
• Paclitaxel Hypersensitivity Reactions: Assessment of the Utility of a Test‐Dose Program

  2006cited by this paper
• Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy

  2005cited by this paper
• ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer.

  2005cited by this paper
• 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).

  2005cited by this paper
• Cisplatinum rechallenge in relapsed ovarian cancer patients with platinum reinduction therapy and carboplatin hypersensitivity

  2004cited by this paper
• Carboplatin hypersensitivity

  2004cited by this paper
• Relationship between a history of systemic allergic reactions and risk of subsequent carboplatin hypersensitivity.

  2003cited by this paper
• Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

  2003cited by this paper
• Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity.

  2003cited by this paper
• A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

  2003cited by this paper
• Hypersensitivity reactions to carboplatin.

  2002cited by this paper
• Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy.

  2002cited by this paper
• Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy.

  2001influential reference
• Prophylaxis for Paclitaxel Hypersensitivity Reactions

  2001cited by this paper
• Predictors of asthma three years after hospital admission for wheezing in infancy.

  2000cited by this paper
• Paclitaxel hypersensitivity reactions related to bee-sting allergy.

  2000cited by this paper
• Clinical features of hypersensitivity reactions to carboplatin.

  1999cited by this paper
• Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma.

  1999cited by this paper
• Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.

  1999cited by this paper
• Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.

  1999cited by this paper
• Improved treatment for cervical cancer--concurrent chemotherapy and radiotherapy.

  1999cited by this paper
• Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer

  1999cited by this paper
• Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.

  1999cited by this paper
• Drug therapy : paclitaxel (Taxol)

  1995cited by this paper
• Paclitaxel (taxol)

  1995cited by this paper
• Carboplatin hypersensitivity in children. A report of five patients with brain tumors

  1995cited by this paper
• Death from anaphylaxis to cisplatin: A case report

  1994cited by this paper
• Hypersensitivity reactions to carboplatin. Report of two patients, review of the literature, and discussion of diagnostic procedures and management

  1994cited by this paper
• Hypersensitivity reactions to carboplatin given to patients with relapsed ovarian carcinoma.

  1994cited by this paper
• Anaphylaxis to carboplatin--a new platinum chemotherapeutic agent.

  1992cited by this paper
• Allergic reactions to carboplatin.

  1992cited by this paper
• Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.

  1991cited by this paper
• Hypersensitivity reactions to carboplatin.

  1991cited by this paper
• Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds.

  1990cited by this paper
• Cancer : Principles and Practice of Oncology

  1982cited by this paper
• Cancer: Principles and Practice of Oncology

  1982cited by this paper

• Evaluating paclitaxel hypersensitivity reaction rates with cetirizine premedication at a large academic cancer center.

  2025cites this paper
• Personalized Risk Assessment for Taxane-Induced Hypersensitivity Reactions: A Systematic Review and Meta-Analysis

  2024cites this paper
• Risk factors of Hypersensitivity Reactions to Carboplatin: A Systematic Review and Meta-analysis.

  2024cites this paper
• Predictors of immediate and delayed cutaneous hypersensitivity reactions to paclitaxel

  2024cites this paper
• A Modified Basophil Activation Test for the Clinical Management of Immediate Hypersensitivity Reactions to Paclitaxel: A Proof-of-Concept Study

  2023cites this paper
• Drug Desensitizations for Chemotherapy: Safety and Efficacy in Preventing Anaphylaxis

  2021cites this paper
• Cutaneous Toxicities in Breast Cancer Patients Receiving Chemotherapy and Targeted Agents--An Observational Clinical Study.

  2021cites this paper
• Characteristics of immediate hypersensitivity reaction to paclitaxel-based chemotherapy in gynecologic cancer patients.

  2020cites this paper
• Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy

  2018cites this paper
• A cohort study of hypersensitivity reaction in patients with epithelial ovarian cancer treated with carboplatin

  2018cites this paper
• Is there any predictor for hypersensitivity reactions in gynecologic cancer patients treated with paclitaxel-based therapy?

  2017cites this paper
• Feasibility of withholding dexamethasone premedication for hypersensitivity reactions associated with paclitaxel administration

  2017cites this paper
• Dermatological adverse events with taxane chemotherapy

  2016cites this paper
• Hypersensitivity reactions to platinum derivatives: findings of new predictive markers.

  2015cites this paper
• Adverse events to nontargeted and targeted chemotherapeutic agents: emphasis on hypersensitivity responses.

  2014cites this paper